BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), together with IASO Biotherapeutics (IASO Bio), jointly announced to deliver an oral presentation on updated data from the Phase I study of IBI326 in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress,

BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the “Company” or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed its previously announced private placement of (i) 4,370,343 common shares at a purchase price of US$5.26.

JEOL Ltd. and SCiLS, a division of Bruker Daltonics, announced that they have concluded a non-exclusive, worldwide distribution agreement for SCiLS Lab MVS software.

After 40 years of fighting the AIDS pandemic, the overriding lesson of history is that the price of pharma greed and vaccine hoarding will be measured in human lives – unless world leaders act now.

Acura Pharmaceuticals, Inc. announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation.

BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced two enhancements to its WatchPAT™ product line that the Company plans to unveil on June 11 during the Virtual SLEEP 2021 Conference, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.

Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 2021 Human Health Innovation Conference on Monday, June 21, 2021 at 8:40 a.m. (ET).

Avivagen Inc. announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will be holding a Virtual Investor Event on Tuesday, June 22, 2021, at 9:00 a.m. - 11:00 a.m. EDT / 3:00 p.m. - 5:00 p.m. CEST.